Tomopenem

Drug Profile

Tomopenem

Alternative Names: CS-023; R 115685; R 1558; RO 4908463

Latest Information Update: 13 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Carbapenems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Community-acquired pneumonia; Gram-negative infections; Gram-positive infections; Skin and soft tissue infections

Most Recent Events

  • 13 May 2008 Discontinued - Phase-II for Gram-negative infections in USA (IV)
  • 13 May 2008 Discontinued - Phase-II for Gram-positive infections in European Union (IV)
  • 13 May 2008 Discontinued - Phase-II for Bacterial infections in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top